Wednesday, July 23, 2014

Interview with Author Dr Hong Xue

This author interview is by Dr Hong Xue, of Hong Kong University of Science and Technology.  Dr Xue's full paper, Application of machine learning to development of copy number variation-based prediction of cancer risk, is available for download in Genomics Insights.

First please summarise for readers the content of your article.

Using machine learning, we have developed a procedure for predicting hereditary cancer risk based on the recurrent (or common) copy number variations occurring in individuals’ constitutional (or germ-line) genomes.

How did you come to be involved in your area of study?

Our research laboratory is a participating laboratory in the International Cancer Genome Consortium, for which I am coordinating the Hong Kong team of researchers from Hong Kong University of Science and Technology, Hong Kong University and the Chinese University of Hong Kong.

What was previously known about the topic of your article?

Some rare somatic forms of copy number variations (CNVs) are observed in cancer tissues. However, hitherto commonly occurring CNVs in individuals’ constitutional genomes, as measure with non-cancerous peripheral leukocytes, are not known to be associated with cancer risk.

How has your work in this area advanced understanding of the topic?

By showing that cancer risk can be assessed based on recurrent CNVs, our work has opened up the use of such CNVs for cancer prediction, and hence predictive medicine for cancers.

What do you regard as being the most important aspect of the results reported in the article?

There are two most important aspects of our work. First, it has increased the usefulness of cancer prediction, thereby enhancing the potential utility of cancer prediction. Secondly, it has identified a number of recurrent CNVs with an ethnic population that are associated with high cancer risk or low cancer risk. Each of the CNV features will open up a line of enquiry to deepen our insight into the underlying factors of cancer development.

You can learn more about Dr Xue and her work here;

Friday, July 18, 2014

Published Recently (7th July– 18th July)

We are pleased to announce the publication of the following peer reviewed papers. 

Sign up to receive email alerts to receive immediate notification of new papers.

Clinical Medicine Insights: Cardiology
Q192R Paraoxonase (PON)1 Polymorphism, Insulin Sensitivity, and Endothelial Function in Essential Hypertensive Men

Clinical Medicine Insights: Dermatology
Ingenol Mebutate

Clinical Medicine Insights: Gastroenterology
Primary and Secondary Prevention of Colorectal Cancer

Clinical Medicine Insights: Oncology
Advanced Extramammary Paget's Disease of the Groin, Penis, and Scrotum

Evolutionary Bioinformatics
Regulation of Human PAX6 Expression by miR-7

Journal of Central Nervous System Disease
Vanishing White Matter Disease in a Spanish Population

Nutrition and Metabolic Insights
Role of Bioactive Food Components in Diabetes Prevention: Effects on Beta-Cell Function and Preservation

Professional Integrity in Scholarly Publishing

Libertas recognizes the importance of our role in the scholarly communication process.  This is manifested by how we address important ethical matters relating to matters such as authorship.  

When he raised a concern with us Dr Selim Mustafa (East Carolina University) was satisfied with how the matter was addressed:

“I am highly impressed with the professional integrity, efficiency, and friendly communication of the editorial staff at Libertas Academia.  Recently, I had an authorship issue which I brought to the attention of the Publisher and CEO (Mr. Tom Hill) of the journal Air, Soil, and Water Research.  The issue was taken very seriously and was handled appropriately in an efficient and timely manner.  I would like to express my sincere appreciation and utmost  respect  for the Publisher and the staff at Libertas Academica for their attention, efforts, and dedication to maintaining the high quality and integrity of their publications.”


Wednesday, July 16, 2014

New Editor in Chief – Clinical Medicine Insights: Arthritis and Musculoskeletal Disorders

We welcome Dr Chuanju Liu as the new Editor in Chief of Clinical Medicine Insights: Arthritis and Musculoskeletal Disorders.

Dr Chuanju Liu is a Professor in the Departments of Orthopedic Surgery and Cell Biology at New York University School of Medicine (NY.)  Dr Liu obtained his PhD in molecular, cellular and developmental biology from Shandong University and obtained post-doctoral training at Yale University.  

Dr Liu has received numerous awards, including the Harold M. Frost Award from the American Society for Bone and Mineral Research, the Dorothy W. Goldstein Award from the Arthritis Foundation, the Career Development Award from National Institute of Health, the Ethelmae Haldan Award for Innovative Science from the Arthritis National Research Foundation, the Kappa Delta Award from the American Academy of Orthopaedic Surgeons, and the Basic Research Award from the American College of Rheumatology.

View the Clinical Medical Insights: Arthritis and Musculoskeletal Disorders journal here

New Editor in Chief - Clinical Medicine Insights: Women's Health

We are happy to announce the addition of Dr Marlene von Friederichs-Fitzwater to the position of Editor in Chief of Clinical Medicine Insights: Women's Health.

Dr Marlene von Friederichs-Fitzwater holds multiple appointments at the University of California, Davis, where she is an Associate Adjunct Professor in the School of Medicine, a Behavioural/Health Disparities Scientist, and Director of the Outreach Research and Education Program at the UC Davis Comprehensive Cancer Centre.  She obtained her PhD at the University of Utah and holds professional memberships in  American Association of Public Health, Association for the Behavioral Sciences and Medical Education, Association for Women in Science, Fellow American Academy on Physician and Patient, Society for Public Health Education, Society of Behavioral Medicine, and the Society of Teachers for Family Medicine.  In 2003 she was honored by the International Biographical Centre (Cambridge, England) with the 21st Century Award for Achievement in Health Communication.  

View Dr von Friederichs-Fitzwater’s profile here


Dr Sibaji Sarkar on Epigenetic Drugs

Epigenetic drugs and what could they be used to treat - Sarah Heerboth, Karolina Lapinska, Nicole Snyder, Meghan Leary, Sarah Rollinson and Sibaji Sarkar.

The whole human body is like a complex computer network from head to toe. However, the complexity of the human body is greater, because unlike electronic devices, the circuits vary or fluctuate according to inputs, signals, and cellular and genetic changes. Interestingly, a lot of stimulators which make these changes come from the environment. In the cellular context, the environment could be the surrounding tissues and the chemicals they secrete. Contrary to an electrical system, the human biological circuitry can be reversibly changed by shutting down one pathway and turning on another. These changes can be irreversible if they are caused by mutations and alterations in genes and chromosomes, and can be reversible if they are caused by epigenetic changes.

Proteins carry out the majority of the cells work. Essentially, a defective protein in a vital pathway of cell survival, cell development, or function could adversely affect the entire cell. When genetic mutations cause these changes, they can be irreversible. Alternatively, epigenetic changes do not change the genetic code and can be reversible. Proteins are produced from RNA that carries a coded message from the gene made of DNA. A mutation in a gene produces altered RNA, and thus, can produce a defective protein. In epigenetic changes, the modification of the segment of DNA often results in increased or decreased RNA production, because the modification often affects the histones or regions of the gene that control the amount of RNA production.

Many of these changes either come from signals from the environment or from the cells surrounding a particular tissue. During the development from embryo to a human being, we need to develop versatile tissues and organs from the same original cell, which requires turning on and shutting off many pathways without losing the gene pool we inherited. These types of changes are not uncommon in a healthy person. Epigenetics plays a huge role in this process.

In certain conditions, however, these changes can be harmful. Recent research has shown that alterations of protein expression due to the increase or decrease of RNA formation by epigenetic mechanisms may alter the balance around tissues that can lead to many diverse diseases and disorders.

Examples of these types of diseases include neurological, cardiovascular, and metabolic problems, as well as cancer. Theoretically, reversal of these changes could fix the problem or improve the condition. Epigenetic drugs are under development and recent studies show that they are capable of changing the imbalance for cure or management of disorders and diseases.

In cancer, the epigenetics events are well studied. Many genes which keep uncontrolled cell growth under check are silenced (do not produce proteins) by epigenetic mechanism. We recently proposed that epigenetic events initiate cancer progenitor cell formation. These progenitor cells are usually not killed by normal cancer therapeutic agents, and hence, cancer relapses. Epigenetic changes are also involved in cancer dug resistance. Recent studies suggest that combination therapy including epigenetics drugs possibly will reduce cancer relapse and will make resistant cancer cells susceptible. Further research is in progress to address these issues.

This group are the authors of the recently published paper Use of Epigenetic Drugs in Disease: An Overview, available for download now in Genetics & Epigenetics


Tuesday, July 8, 2014

Dr Greg Kearney (East Carolina University) on publishing in Environmental Health Insights

We asked Dr Kearney about his experience publishing in Environmental Health Insights.  Here’s what he told us:

“My experience in publishing with Environmental Health Insights was positive from the beginning of the initial manuscript submittal, to the published product. The peer reviewers provided helpful suggestions, while the editorial  and production staff kept me fully informed of the paper's process every step of the way.  I recommend Libertas Academica for anyone that is serious about publishing their research in an efficient, friendly and professional manner.”

Read and download Dr Kearney’s paper Eastern Carolina Asthma Prevention Program (ECAPP): An Environmental Intervention Study Among Rural and Underserved Children with Asthma in Eastern North Carolina

Friday, July 4, 2014

Published Recently (13rd June – 5th July)

We are pleased to announce the publication of the following peer reviewed papers.  Sign up to receive email alerts to receive immediate notification of new papers.

Analytical Chemistry Insights

Preliminary Development of a Fiber Optic Sensor for Measuring Bilirubin

Bioinformatics and Biology Insights

In Silico Studies of Medicinal Compounds Against Hepatitis C Capsid Protein from North India

Biomarkers in Cancer

Biomarkers of HIV-associated Cancer

Biomarker Insights

DNA Methylation at the Novel CpG Sites in the Promoter of MED15/PCQAP Gene as a Biomarker for Head and Neck Cancers

Integrative Genomic Analysis for the Discovery of Biomarkers in Prostate Cancer

Cancer Growth and Metastasis

Systemic Platelet-activating Factor Receptor Activation Augments Experimental Lung Tumor Growth and Metastasis

Clinical Medicine Insights: Arthritis and Musculoskeletal Disorders

Modern Rehabilitation in Osteoporosis, Falls, and Fractures

Clinical Medicine Insights: Cardiology

Blood Pressure Control and Exaggerated Blood Pressure Response in Nigerians with Essential Hypertension

Clinical Medicine Insights: Case Reports

Bilateral Carotid Paraganglioma: Surgery and Radiotherapy

Cabergoline Treatment in Invasive Giant Prolactinoma

Clinical Medicine Insights: Dermatology

A Rare Finding of Onychoheterotopia (Ectopic Nail) in a Case of Systemic Sclerosis

Clinical Medicine Insights: Ear, Nose and Throat

Laser Posterior Cordotomy: Is it a Good Choice in Treating Bilateral Vocal Fold Abductor Paralysis?

Clinical Medicine Insights: Gastroenterology

Liver Function Test Abnormalities in Patients with Inflammatory Bowel Diseases: A Hospital-based Survey

Clinical Medicine Insights: Trauma and Intensive Medicine

Role of Damage Control Orthopedics and Early Total Care in the Multiple Injured Trauma Patients

Clinical Medicine Insights: Women's Health

Weight Loss Intervention in Survivors of ER/PR-negative Breast Cancer

Environmental Health Insights

Eastern Carolina Asthma Prevention Program (ECAPP): An Environmental Intervention Study Among Rural and Underserved Children with Asthma in Eastern North Carolina

Evolutionary Bioinformatics

Influence of Modularity and Regularity on Disparity of Atelostomata Sea Urchins

Genomics Insights

Application of Machine Learning to Development of Copy Number Variation-based Prediction of Cancer Risk

Health Services Insights

Ambulatory and Hospital-based Quality Improvement Methods in Israel

International Journal of Insect Science

The Developmental Biology of Grain-Sucking Bug, Stenocoris elegans Blöte, on Upland Rice

Medical Equipment Insights

3D Laparoscopic Monitors

Ophthalmology and Eye Diseases

Safety and Efficacy of Cyclosporine in the Treatment of Chronic Dry Eye
Impact of Parental History of Myopia on the Development of Myopia in Mainland China School-Aged Children

Perspectives in Medicinal Chemistry

Pathways for Small Molecule Delivery to the Central Nervous System Across the Blood-Brain Barrier

Reproductive Biology Insights

Impact of Controlled Ovarian Hyperstimulation on Thyroid Function

Thursday, July 3, 2014

Dr Abdalla Bowirrat on Devic’s Disease

Neuromyelitis optica (NMO) was described by Eugène Devic in 1894 and it is known since then as Devic’s NMO (Devic’s disease). It is uncommon heterogeneous inflammatory demyelinating neuro-immunological disease of the central nervous system (CNS) that is characterized by severe attacks of optic neuritis (ON) and transverse myelitis with contiguous spinal cord MRI lesion extending over three or more vertebral segments, and seropositivity for NMO-IgG (anti-aquaporin-4 (anti-AQP4), which has been recently described as a sensitive and specific marker for NMO.1-8

NMO affects both genders with three to nine times more prevalence in women than in men, the age of onset ranges from childhood to late adulthood, with a median of 20 to 50 years among adults and 4.5 years among children.

Cases of NMO have been reported from different parts of the world and different races, although the disease is more prevalent in areas with black, Asian, and Indian populations, in which NMO constitutes from 15% to 57% of demyelinating diseases.

 Controversy about whether NMO is a subtype of multiple sclerosis (MS) or a different disease has persisted for years. However, a series of clinical, radiological, histopathologic, and immunologic studies provide evidence that NMO and NMO disorders are distinct from MS in spite of common pathologic characteristics, like demyelination of CNS.9-10

Clinical Manifestations

Sequential or simultaneous optic neuritis (ON) and transverse myelitis are typical features of NMO. Optic neuritis usually presents with unilateral or, less often, bilateral ocular pain and visual loss.

 Myelitis caused by NMO, often present with complete transverse myelitis with tetraplegia or paraplegia and a well-defined sensory level and sphincter dysfunction, and may be accompanied by pain and paroxysmal tonic spasms of the trunk and the extremities. Prominent dysesthetic, radicular pain, possibly associated with Lhermitte symptoms, is common and may occur in up to 35% of acute severe myelitis attacks in relapsing NMO.11, 12 The lesion may extend toward the brain stem and cause hiccups, intractable nausea, or respiratory  failure.11-13 

Treatment Options

Today, the first-line therapy with Azathioprine or Rituximab for severe disease course of NMO calls for prompt initiation of immunosuppressive treatment once the diagnosis of NMO has been confirmed. IVIg may be used as the first-line therapy for children or for patients with contraindication to immunosuppressive therapies.

Second-line therapy of NMO: In the case of side effects or poor response, treatment can be switched from azathioprine to rituximab or vice versa, or to mycophenolate mofetil, methotrexate, or mitoxantrone.

The third-line therapy for NMO should be applied if disease progression occurs, and if the above treatments fail, the newer agents such as Tocilizumab should be given with combination therapy (combination of steroid plus cyclosporin-A or methotrexate or azathioprine; combination of immu¬nosuppression plus intermittent plasma exchange (PE); or combination of rituximab with methotrexate or intravenous immunoglobulins (IVIg).14

Treatment goes beyond medicine to include occupational therapists, physiotherapists, and social service professionals in cases of complex disability.


For sufferers of NMO, effective treatments are becoming available. The recognition of a specific marker NMO-IgG has not only facilitated the diagnosis of the condition but also presented a rational approach to the cure of the condition. Not only there are therapies that can decrease the impact of relapsing attacks and prevent attacks, but a therapy may be also possible by reduced-dose myeloablative regimens and hematopoietic cell replacement. Moreover, with reduced-dose myeloablative regimens, the mortality rate is low and approaching 1%.

Prof. Dr. Abdalla Bowirrat is author of the recently published paper Systemic Lupus Erythematosus (SLE) Complicated by Neuromyelitis Optica (NMO – Devic’s Disease): Clinic-Pathological Report and Review of the Literature, available for download now in Clinical Medicine Insights: Case Reports.


1. Lennon VA, Wingerchuk DM, Kryzer TJ, et al. A serum autoantibody marker of neuromyelitis optica: distinction from multiple sclerosis. Lancet. 2004;364:2106–12.

2. Wingerchuk DM, Hogancamp WF, O’Brien PC, Weinshenker BG. The clinical course of neuromyelitis optica (Devic’s syndrome). Neurology. 1999;53:1107–14.

3. Kim W, Kim S-H, Huh S-Y, Kim HJ. Brain abnormalities in neuromyelitis optica disorder. Mult Scler Int. 2012;2012:735486.

4. Choi SI, Lee YJ, Kim DW, Yang JY. A case of neuromyelitis optica misdiag¬nosed as cervicogenic headache. Korean J Pain. 2014;27:77–80.

5. Papadopoulos MC, Verkman AS. Aquaporin 4 and neuromyelitis optica. Lancet Neurol. 2012;11:535–44.

6. Trebst C, Jarius S, Berthele A, et al. Neuromyelitis Optica Study Group (NEMOS). Update on the diagnosis and treatment of neuromyelitis optica: recommendations of the neuromyelitis optica Study group (NEMOS). J Neurol. 2014;261:1–16.

7. Jarius S, Wildemann B. The history of neuromyelitis optica. J Neuroinflammation. 2013;10:8.

8. Kimbrough DJ, Fujihara K, Jacob A, et al. Treatment of neuromyelitis optica: review and recommendations. Mult Scler Relat Disord. 2012;1:180–7.

9. Lennon VA, Wingerchuk DM, Kryzer TJ, et al. A serum autoantibody marker of neuromyelitis optica: distinction from multiple sclerosis. Lancet 2004;364: 2106–12.

10. Scolding N. The differential diagnosis of multiple sclerosis. J Neurol Neurosurg Psychiatry. 2001;71:ii9–ii15.

11. Wingerchuk DM, Hogancamp WF, O’Brien PC, et al. The clinical course of neuromyelitis optica (Devic’s syndrome). Neurology. 1999;53:1107–14.

12. Papais-Alvarenga RM, Carellos SC, Alvarenga MP, et al. Clinical course of optic neuritis in patients with relapsing neuromyelitis optica. Arch Ophthalmol. 2008;126:12–6.

13. Misu T, Fujihara K, Nakashima I, et al. Intractable hiccup and nausea with periaqueductal lesions in neuromyelitis optica. Neurology. 2005;65:1479–82.

14. Trebst C, Jarius S, Berthele A, et al. Neuromyelitis Optica Study Group (NEMOS). Update on the diagnosis and treatment of neuromyelitis optica: recommendations of the neuromyelitis optica Study group (NEMOS). J Neurol. 2014;261:1–16.

Dr Mussa Almalki on Giant Prolactinomas

A prolactinoma is a non-cancerous, iatrogenic lump of the pituitary gland, which triggers over secretion of the hormone “prolactin”. While it can occur in both sexes and at any age, it is more common in women aged 20-50 years. It is the most common type of pituitary tumor and is classified according to tumor size: microadenomas are <10 mm and macroadenomas are >10mm. A rare type more commonly identified in men, called giant prolactinoma, is diagnosed for pituitary tumors >4cm.

A giant prolactinoma causes symptoms due to hyperprolactinemia and/or by tumor size growth, resulting in pressure on adjacent structures causing headache, blurred or loss of peripheral vision due to optic nerves compression as well as symptoms of pituitary dysfunctions (hypopituitarism) including hypothyroidism, adrenal insufficiency and growth hormone deficiency.

In women, hyperprolactinemia can cause irregular periods or complete cessation of menstrual cycles, breast milk production and infertility. Some women may experience a loss of libido. In men it can also cause infertility with loss of sex drive and erectile dysfunction.  

Diagnosis of giant prolactinoma is confirmed by very high circulatory levels of prolactin, usually more than 1000 mg/dl and evidence of pituitary tumor through magnetic resonance imaging (MRI) scan. Tests to assess visual involvement maybe requested to determine if pituitary tumor growth has impaired sight or peripheral vision.

A giant prolactinomas can be effectively treated with medications to reduce blood prolactin levels and shrinkage tumor size. Commonly prescribed medications include Bromocriptine and Cabergoline. Usually these medications need to be maintained for life, as recurrence is highly likely if medication is discontinued.

Surgical options either through the nasal cavity or through the upper part of the skull maybe viable for patients who failed to respond to medications or if the tumor growth has spread to adjacent brain tissues causing rapid loss of vision.

Radiation therapy may also be an option for people who do not respond to medications and are not candidates for surgical intervention.

Dr. Mussa Almalki is author of the recently published paper Cabergoline Treatment in Invasive Giant Prolactinoma, available for download now in Clinical Medicine Insights: Case Reports.

Wednesday, June 25, 2014

Benefits for Peer Reviewers

All submitted manuscripts to Libertas are subject to peer review by two to three peer reviewers per manuscript.  These reviews go toward the peer review report completed by the editor in chief or associate editor.

Because of our extensive peer review practice, and because of natural growth in the quantity of submissions received, we now seek new volunteer peer reviewers. 

Being a peer reviewer can also benefit the individuals who are involved:

  • Reviewers gain more recognition and exposure among other authors and contributors in their field

  • Reviewers make useful connections within the science community, helping to build reputations among other scientists

  • Our online platform and automated processes for handling manuscripts mean that less time is spent on processes that aren’t related to feedback and therefore peer review has become a more efficient experience

  • There are no limitations or expectations with the amount of papers reviewed. Invitations can be declined or accepted to fit in with reviewers’ schedules

  • Participating in peer reviews provides reviewers with insights on how to review papers and in turn can help in their own publishing experiences. Reviewers can learn how to understand what is expected from their own paper as well as how to respond to peer reviewer comments

We invite you to register as a volunteer peer reviewer. 

All applications are assessed by the editor in chief or associate editor of the journal, who may apply additional criteria at their discretion.

Apply to become a peer reviewer today!

Wednesday, June 18, 2014

What We Get Asked Here at Libertas

Customer satisfaction is something that we take very seriously at Libertas. One of our areas of focus is ensuring that all queries are answered quickly and efficiently.

Below is a summary of a few frequently asked questions:

Do you charge article processing fees?

Because the majority of our journals are open access we charge article processing fees. These vary depending on journal. However we do not charge any additional fees for figures, word count, or images. For more information on fees please visit our website.

Are your journals indexed with PubMed?

We are aware that PubMed indexing is very important to authors and readers.  Many of our journals are indexed with PubMed, and more are being added. To find out which journals are indexed with PubMed please visit our journals homepage.

Do your journals have an Impact Factor?

At this stage many of our journals are too new to have an impact factor, with the exception of Evolutionary Bioinformatics with an impact factor of 1.326.

I am interested in becoming a peer reviewer or editorial board member

We seek high calibre individuals to join both our editorial boards and peer reviewer pools. Acceptance is dependent on several factors that are stipulated on our website and we welcome applications from individuals who meet the criteria.

Is my manuscript suitable for submission?

We offer an Ask an Editor In Chief service which allows you the chance to send your draft manuscript or abstract to the editor in chief who can then consider whether they feel your manuscript is within the aims and scope of the journal. Visit our website to utilise this service.

Please do not hesitate to contact us with any questions or requests and we will respond in a timely manner.

Friday, June 13, 2014

Published This Week

We are pleased to announce the publication of the following peer reviewed papers.  Sign up to receive email alerts to receive immediate notification of new papers.

Analytical Chemistry Insights

Determination of Xanthine in the Presence of Hypoxanthine by Adsorptive Stripping Voltammetry at the Mercury Film Electrode 

Bioinformatics and Biology Insights

DOR – a Database of Olfactory Receptors – Integrated Repository for Sequence and Secondary Structural Information of Olfactory Receptors in Selected Eukaryotic Genomes 

High-throughput Methods Redefine the Rumen Microbiome and Its Relationship with Nutrition and Metabolism 

Identification of Chicken Pulmonary miRNAs Targeting PB1, PB1-F2, and N40 Genes of Highly Pathogenic Avian Influenza Virus H5N1 In Silico 

A Protocol for mtGenome Analysis on Large Sample Numbers  

Cancer Growth and Metastasis

Cancer Chemoprevention: Current State of the Art 

Clinical Medicine Insights: Cardiology

Left Atrial Appendage Closure Devices  

Clinical Medicine Insights: Pathology

Thoracic Epidural Teratoma: Case Report and Review of the Literature 

Clincial Medicine Insights: Reproductive Health

Coenzyme Q10 Supplementation and Oocyte Aneuploidy in Women Undergoing IVF–ICSI Treatment 

Ketoconazole Inhibits Ovulation as a Result of Arrest of Follicular Steroidogenesis in the Rat Ovary

Management of Vaginal Atrophy: Implications from the REVIVE Survey 

Evolutionary Bioinformatics

Similarity/Dissimilarity Analysis of Protein Sequences Based on a New Spectrum-Like Graphical Representation 

Genetics and Epigenetics

Effect of FTO Gene and Physical Activity Interaction on Trunk Fat Percentage Among the Newfoundland Population 

Japanese Clinical Medicine

A Case of Giant Osteoma in the Middle Turbinate of a Child 

Ophthalmology and Eye Diseases

Indications for Surgical Removal of the Eye in Rural Areas in Cameroon 

Substance Abuse: Research and Treatment

Prevalence and Predictors of Harmful Khat Use Among University Students in Ethiopia 


Wednesday, June 11, 2014

78% of Authors Rate their Interactions with Editors in Chief as Very Good

We survey all authors after their articles are published in our journals.  We ask them to rate various aspects of their experience to ensure that we're meeting our commitments to them.  

Our research shows that:

  • 78% of authors surveyed rated the quality of their interactions with editors in chiefs and associate editors as very good. 22% of authors rated the quality of their interactions as good.

  • 74% of authors surveyed rated the speed and efficiency of manuscript processing at Libertas as very good. 22% of authors rated the speed and efficiency of manuscript processing as good.

  • 74% of authors surveyed rated the quality of interactions with Libertas staff as very good. 22% of authors rated the quality of their interactions as good.

Let us know what you think